SecBot SecBot

BNTX drug pipeline

BioNTech SE · 7 rated drugs
$85.60
+0.7% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
7
1 bearish · 1 mixed · 5 neutral
Phase 3 trials
7
3 with results posted

Upcoming catalysts

1 dated
  1. Nov 2026
    RO7198457 intravenous (IV)
    Phase 2 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketAt least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.

gotistobart Updated Aug 28

What to watch

The key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.

Bull case
  • At the European Lung Cancer Congress 2026, gotistobart showed a 54% reduction in risk of death in squamous NSCLC, a strong efficacy signal that supports the ongoing Phase 3 PRESERVE-003 trial.
  • Updated overall survival data from the Phase 3 PRESERVE-003 trial will be presented at WCLC 2026 (Sept 12-15), providing a near-term catalyst within ~2 weeks.
  • BioNTech has a deep late-stage oncology pipeline with 25+ Phase 2/3 trials including 13 pivotal studies, and analyst consensus is strongly bullish (22 analysts: 22 buy/strong buy, 0 sell, mean price target $121 implying ~26% upside).
Bear case
  • Gotistobart's mechanism of action is not well-characterized in public disclosures, making it harder to assess competitive differentiation vs. established checkpoint inhibitors and other immunotherapies in NSCLC.
  • BioNTech's oncology pipeline is broad but pre-commercial; the company posted a €531.9M GAAP net loss in Q1 2026 and its COVID vaccine revenue continues to decline, meaning pipeline setbacks carry more weight.
  • Institutional activity is mixed, Citadel, Jane Street, and Bank of America trimmed BNTX positions in Q2 2026, while FINRA short-volume ratio recently exceeded 0.30, indicating elevated short-selling flow.
◆ mixed
Impact
PhasePhase 3
Time to marketBLA submission planned for 2026 (endometrial cancer). If filed and accepted, a potential FDA decision would likely come in 2027. A China NDA for breast cancer was accepted by the NMPA in April 2026.

BNT323 trastuzumab pamirtecan Updated Oct 26

What to watch

The next hard catalyst for BNT323 is the planned BLA submission to the FDA for HER2-expressing endometrial cancer, which BioNTech has guided for 2026. Watch for the acceptance announcement and whether a PDUFA date is set. The mixed DYNASTY-Breast02 results announced today could complicate the regulatory narrative, particularly the safety signal. Separately, the Fern-EC-01 Phase 3 trial (NCT06340568) in endometrial cancer is ongoing and its readout would be another major catalyst.

Bull case
  • BNT323 met its primary PFS endpoint in two Phase 3 trials (DYNASTY-Breast01 in China and DYNASTY-Breast02 globally), demonstrating clinical proof of concept across HER2-positive and HER2-low breast cancer populations.
  • Phase 2 endometrial cancer data showed a 47.9% objective response rate (over 70% in HER2 IHC 3+ patients), supporting a planned 2026 BLA filing in an area of high unmet need.
  • BioNTech has deep financial resources (€16.8B liquidity per a July 2026 Seeking Alpha analysis) to fund the oncology pivot and BNT323's development without near-term dilution risk.
Bear case
  • DYNASTY-Breast02 results announced today showed only 'modest' PFS improvement with the companies themselves citing 'limited potential patient benefit', a weak efficacy signal that may limit commercial opportunity in the large HR+/HER2-low segment.
  • A higher rate of interstitial lung disease (ILD) was reported in DYNASTY-Breast02 compared to prior trials, including severe and fatal events, a safety concern that could complicate regulatory filings and label negotiations.
  • BNT323 faces entrenched competition from Enhertu (trastuzumab deruxtecan, AstraZeneca/Daiichi Sankyo), the current standard-of-care HER2 ADC with multi-billion-dollar sales, and from Kadcyla (Roche), plus a crowded field of other HER2 ADCs in development.
▼ bearish
Impact
PhasePhase 2/3 (pivotal)
Time to marketIf the OS readout is positive, a regulatory filing could follow in 2027-2028. If OS also misses, the program is likely terminated for this indication.

tenumomeran tenumomeran/raplemomeran Updated Nov 4

What to watch

The next catalyst is the overall survival (OS) readout from the AHEAD-MERIT trial, which has no announced date. If OS is positive, it could salvage the program despite the PFS miss; if OS also misses, BNT113 is effectively dead for this indication. Watch for BioNTech's disclosures on the timing of the OS analysis.

Bull case
  • The Independent Data Monitoring Committee recommended continuing the trial to evaluate overall survival, meaning the OS endpoint remains a viable path to a positive trial.
  • Precedents exist for cancer immunotherapies that improved OS after failing to extend PFS, as noted by Fierce Biotech.
  • BNT113 received FDA Fast Track designation in January 2026 based on preliminary AHEAD-MERIT data, signaling some regulatory interest.
Bear case
  • The Phase 3 portion of AHEAD-MERIT failed its first dual primary endpoint of progression-free survival (PFS) on October 13, 2026, with no hazard ratio or effect size disclosed, raising doubts about the drug's efficacy.
  • Analysts became 'significantly' less confident that BNT113 will extend overall survival after the PFS miss, per Fierce Biotech reporting.
  • The PFS miss is BioNTech's third mRNA cancer immunotherapy setback, adding to a pattern of disappointing results in the space.
● neutral
Impact
PhasePreclinical / Discovery (no clinical trials registered)
Time to marketUnknown — if currently preclinical, typical timelines would be 5-8+ years from IND filing to potential approval, assuming successful development.

beruzatatug pelitecan Updated Oct 24

What to watch

Beruzatatug pelitecan is not a near-term catalyst for BNTX. Investors should watch BioNTech's more advanced oncology assets, trastuzumab pamirtecan (HER2 ADC, Phase 2 data reported), pumitamig (bispecific, Phase 3), and gotistobart (Phase 3), for nearer-term value drivers. The company also faces the transition from COVID-19 vaccine revenue to oncology; any early-stage ADC is too far out to factor into a trading thesis today.

Bull case
  • BioNTech has established expertise in oncology drug development with a deep pipeline of over 25 Phase 2/3 trials, providing a strong platform for ADC innovation.
  • The bispecific ADC format (combining two tumor-targeting domains with a potent chemotherapy payload) represents an emerging frontier in cancer therapy that could offer differentiated efficacy versus traditional ADCs.
  • BioNTech has a substantial cash position (~€17.2 billion as of FY2025), providing ample resources to advance preclinical assets through development without near-term financing pressure.
Bear case
  • Beruzatatug pelitecan has zero public clinical data, no trials registered, no press releases, no SEC filings, making it impossible to assess its therapeutic potential or competitive positioning.
  • BioNTech's existing ADC trastuzumab pamirtecan (HER2-targeted) already showed a 47.9% response rate in endometrial cancer, raising questions about where another bispecific ADC fits and whether its mechanism offers meaningful differentiation.
  • The bispecific ADC space is increasingly crowded, with competition from well-capitalized players like AbbVie, Pfizer, and numerous biotechs, making differentiation and eventual commercial success uncertain.
● neutral
Impact
PhaseNot stated
Time to marketNot stated

BNT317 Updated Oct 24

What to watch

Investors should not base any trading decisions on BNT317, as no verifiable public data exists on this candidate. BioNTech's share price (BNTX ~$88.12) will continue to be driven by its more advanced oncology assets (gotistobart, pumitamig, trastuzumab pamirtecan) and its COVID-19 vaccine franchise.

Bear case
  • No public data exists for BNT317, it may be a retired code, a misidentified pipeline designation, or an extremely early preclinical candidate. Investors cannot evaluate safety, efficacy, or commercial potential.
  • BioNTech's ~€17.2B cash position funds a broad pipeline of 25+ Phase 2/3 trials, but BNT317 is absent from all disclosed pipeline lists, suggesting it has been deprioritized or never entered development.
  • Web and database searches across ClinicalTrials.gov, FDA records, press releases, and SecBot's ingested datasets returned zero results for BNT317.
● neutral
Impact
PhasePhase 1/2
Time to marketSeveral years away at minimum. The drug is still in Phase 1/2 testing with no registrational trial initiated. Even if Phase 2 data support advancement, a Phase 3 program would take multiple years to complete before any regulatory filing.

sacituzumab drozuntecan Updated Nov 4

What to watch

Watch for further Phase 2 data readouts from the ongoing NCT05438329 trial, particularly in ovarian cancer (where Fast Track designation was granted) and NSCLC. Any announcement of a planned registrational Phase 3 trial would be the next meaningful catalyst. For now, the drug is too early-stage to be a standalone driver for BNTX shares.

Bull case
  • TROP2 is a validated ADC target with blockbuster precedent (Gilead's Trodelvy generated over $1B in 2024 sales), and a next-generation ADC could capture market share if it shows better efficacy or safety.
  • Early Phase 2 data for the pumitamig + BNT325 combination in first-line TNBC showed encouraging efficacy with a manageable safety profile, suggesting potential as a future combination backbone.
  • FDA Fast Track designation for platinum-resistant ovarian cancer provides regulatory pathway advantages including more frequent FDA engagement and potential priority review if data support it.
Bear case
  • The TROP2 ADC space is increasingly crowded with competitors including Gilead's approved Trodelvy, AstraZeneca/Daiichi's datopotamab deruxtecan, and Merck's sacituzumab tirumotecan, making differentiation challenging.
  • The drug is still in Phase 1/2 with no registrational trial started, meaning any potential approval is years away and clinical failure risk remains high.
  • For BioNTech, this is one of many pipeline assets; even positive data would have a limited impact on BNTX shares given the company's size and diversified pipeline.
● neutral
Impact
PhaseNot stated
Time to marketUnknown — no clinical or regulatory data available

BNT329 Updated Oct 24

What to watch

Do not trade BNTX based on BNT329, there is no publicly available data on this candidate. For BioNTech investors, the relevant catalysts are the company's later-stage oncology pipeline (individualized neoantigen therapies, BNT211 for solid tumors, and BNT122) and COVID-19 vaccine franchise economics. Watch for any BNT329 disclosure in BioNTech's R&D day presentations or annual pipeline updates if and when it progresses.

Bull case
  • BioNTech (BNTX) is a proven mRNA platform company with a market cap supported by its COVID-19 vaccine (Comirnaty) partnership with Pfizer, providing substantial financial resources to develop a deep pipeline of oncology and infectious disease candidates.
  • If BNT329 is a preclinical asset from BioNTech's R&D engine, it could eventually contribute to a pipeline that has already produced validated mRNA-based therapeutics.
Bear case
  • BNT329 is entirely absent from public records, no clinical trials, no pipeline disclosures, no press releases. It may be a discontinued program, a very early preclinical project that may never reach the clinic, or an internal code that was never progressed.
  • With zero available data on mechanism, target, or development stage, BNT329 cannot be evaluated as a meaningful driver of BNTX stock. It represents no identifiable catalyst for investors.
  • BioNTech's stock (currently ~$88, down ~1.7% on last trade) trades primarily on its COVID-19 vaccine franchise and higher-profile oncology programs (BNT122, BNT211, etc.), not on obscure early pipeline entries.

Other drugs in filings and trials

no drug report yet

Clinical trials

15 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
RO7198457 intravenous (IV)A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal CancerPhase 2Active not recruiting327Nov 2026
BNT162b2 VaccineA Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgePhase 3Completed5,240Sep 22, 2026
BNT162b2 (2025/2026 formulation)A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19Phase 3Completed344Jul 24, 2026
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram doseA Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy ChildrenPhase 3Completed4,338Jul 10, 2026
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 YearsPhase 3Completed774May 1, 2026
BNT142Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid TumorsPhase 2Terminated73Dec 22, 2025
BNT166aA Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox VaccinesPhase 2Completed · results96Aug 25, 2025
PM8002PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaPhase 2Completed35Jul 24, 2025
Investigational Influenza VaccineA Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy PeoplePhase 2Completed · results1,353Jul 15, 2025
BNT165cA Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against MalariaPhase 2Completed · results163May 28, 2025
BNT162b2 (Omi XBB.1.5)A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy IndividualsPhase 3Completed · results1,051Mar 13, 2025
tenumomeranHARE-40: HPV Anti-CD40 RNA vaccinEPhase 2Completed30Nov 1, 2023
Biological/Vaccine: BNT162b2 10mcgStudy to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy ChildrenPhase 3Completed · results11,837Oct 4, 2023
BNT162b1Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy IndividualsPhase 3Completed · results46,969Feb 10, 2023
BNT162b2Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy PopulationPhase 2Completed960Feb 7, 2021